NCT05956626Phase 2, phase 3Active not recruiting

A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease

Study sponsor: Ocugen

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-09-28Estimated
Enrollment · participants51Estimated
Source updated2026-07-31Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview